Language:

Hypertriglyceridaemia and risk of coronary artery disease

Nature reviews cardiology, 2017-07, Vol.14 (7), p.401-411 [Peer Reviewed Journal]

COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Jul 2017 ;ISSN: 1759-5002 ;EISSN: 1759-5010 ;DOI: 10.1038/nrcardio.2017.31 ;PMID: 28300080

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Hypertriglyceridaemia and risk of coronary artery disease
Author: Reiner, Zeljko
Subjects: Cardiovascular disease ; Cholesterol ; Complications and side effects ; Coronary Artery Disease - epidemiology ; Coronary Artery Disease - metabolism ; Coronary Artery Disease - prevention & control ; Coronary heart disease ; Humans ; Hypertriglyceridemia - drug therapy ; Hypertriglyceridemia - epidemiology ; Hypertriglyceridemia - metabolism ; Hypolipidemic Agents - pharmacology ; Low density lipoprotein ; Risk Factors ; Treatment Outcome ; Triglycerides ; Triglycerides - blood ; Triglycerides - metabolism
Is Part Of: Nature reviews cardiology, 2017-07, Vol.14 (7), p.401-411
Description: An elevated serum level of LDL cholesterol is a well-known risk factor for cardiovascular disease (CVD), but the role of elevated triglyceride levels is debated. Controversies regarding hypertriglyceridaemia as an independent risk factor for CVD have occurred partly because elevated triglyceride levels are often a component of atherogenic dyslipidaemia - they are associated with decreased levels of HDL cholesterol and increased levels of small dense LDL particles, which are highly atherogenic. Findings from several large studies indicate that elevated levels of triglycerides (either fasting or nonfasting) or, more specifically, triglyceride-rich lipoproteins and their remnants, are independently associated with increased risk of CVD. Possible mechanisms for this association include excessive free fatty acid release, production of proinflammatory cytokines, coagulation factors, and impairment of fibrinolysis. Therapeutic targeting of hypertriglyceridaemia could, therefore, reduce CVD and cardiovascular events, beyond the reduction achieved by LDL-cholesterol lowering. Elevated triglyceride levels are reduced with lifestyle interventions and fibrates, which can be combined with omega-3 fatty acids. Some new drugs are on the horizon, such as volanesorsen (which targets apolipoprotein C-III), pemafibrate, and others. However, CVD outcome studies with triglyceride-lowering agents have produced inconsistent results, meaning that no convincing evidence is available that lowering triglycerides by any approach can reduce mortality.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 1759-5002
EISSN: 1759-5010
DOI: 10.1038/nrcardio.2017.31
PMID: 28300080
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Hypertriglyceridaemia and risk of coronary artery disease

COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Jul 2017 ;ISSN: 1759-5002 ;EISSN: 1759-5010 ;DOI: 10.1038/nrcardio.2017.31 ;PMID: 28300080

Searching Remote Databases, Please Wait